Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 13/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 10/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 10/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 10/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 10/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420442 | 0.86 | GRIN1 (0.42) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL8873482 | 0.83 | GRIN1 (0.41) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL8873485 | 0.83 | GRIN1 (0.41) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL5974273 | 0.81 | GRIN1 (0.60) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL7779818 | 0.80 | GRIN1 (0.46) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL10285831 | 0.80 | GRIN1 (0.47) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL2639502 | 0.79 | GRIN1 (0.45) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL8609931 | 0.79 | GRIN1 (0.45) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL2640204 | 0.76 | GRIN1 (0.66) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B | |
| SCHEMBL2639494 | 0.75 | GRIN2D (1.00) | GRIN1GRIN2DGRIN3BGRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0647137-A4 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF. | UNIV CALIFORNIA WEBER ECKARD (US) | 1998-09-16 | — | — | EP | claimed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | claimed |
| JP-H08501283-A | — | — | 1996-02-13 | — | — | JP | claimed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | claimed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | UNIV NORTHWESTERN (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | UNIV NORTHWESTERN (US) | 2017-03-16 | — | — | US | disclosed |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
| EP-0647137-B1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | UNIV CALIFORNIA (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-0647137-B1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | UNIV CALIFORNIA (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-0647137-A4 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF. | UNIV CALIFORNIA WEBER ECKARD (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998005337-A1 | USE OF GABA AND NMDA RECEPTOR LIGANDS FOR THE TREATMENT OF MIGRAINE HEADACHE | COCENSYS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GRIN1 202/4885GRIN2D 30/4885GRIN3B 207/4885 |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2D 15/4885GRIN3B 5/4885 |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | GRIN1 1/4885GRIN2D 8/4885GRIN3B 6/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | GRIN1 202/4885GRIN2D 30/4885GRIN3B 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.